Monarch Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.07M Buy
127,572
+2,730
+2% +$71.4K 0.7% 43
2026
Q1
$3.51M Sell
124,842
-1,000
-0.8% -$26.6K 0.86% 39
2025
Q4
$3.13M Buy
125,842
+4,297
+4% +$108K 0.77% 41
2025
Q3
$3.1M Buy
121,545
+1,425
+1% +$35.2K 0.76% 40
2025
Q2
$2.91M Buy
120,120
+4,340
+4% +$101K 0.78% 41
2025
Q1
$2.93M Buy
115,780
+398
+0.3% +$10.4K 0.82% 40
2024
Q4
$3.06M Buy
115,382
+8,152
+8% +$221K 0.84% 39
2024
Q3
$3.1M Buy
107,230
+1,098
+1% +$32K 0.84% 40
2024
Q2
$2.97M Sell
106,132
-2,094
-2% -$57.7K 0.87% 37
2024
Q1
$3M Sell
108,226
-314
-0.3% -$8.71K 0.85% 39
2023
Q4
$3.12M Sell
108,540
-1,573
-1% -$47.6K 0.95% 36
2023
Q3
$3.65M Buy
110,113
+205
+0.2% +$7.25K 1.17% 32
2023
Q2
$4.03M Buy
109,908
+1,565
+1% +$60.9K 1.22% 31
2023
Q1
$4.42M Buy
108,343
+250
+0.2% +$10.8K 1.36% 28
2022
Q4
$5.54M Sell
108,093
-5,074
-4% -$243K 1.7% 19
2022
Q3
$4.95M Sell
113,167
-1,917
-2% -$93.2K 1.61% 21
2022
Q2
$6.03M Sell
115,084
-270
-0.2% -$13.8K 1.8% 20
2022
Q1
$5.97M Sell
115,354
-450
-0.4% -$23.3K 1.58% 24
2021
Q4
$6.84M Sell
115,804
-3,635
-3% -$180K 1.75% 22
2021
Q3
$5.14M Buy
119,439
+632
+0.5% +$28K 1.43% 30
2021
Q2
$4.65M Sell
118,807
-300
-0.3% -$11.7K 1.33% 29
2021
Q1
$4.32M Buy
119,107
+4,340
+4% +$154K 1.28% 29
2020
Q4
$4.22M Sell
114,767
-7,578
-6% -$278K 1.33% 29
2020
Q3
$4.26M Sell
122,345
-754
-0.6% -$26.4K 1.48% 27
2020
Q2
$3.82M Sell
123,099
-6,848
-5% -$233K 1.4% 28
2020
Q1
$4.02M Sell
129,947
-565
-0.4% -$19.3K 1.64% 26
2019
Q4
$4.85M Buy
130,512
+2,161
+2% +$77K 1.58% 27
2019
Q3
$4.38M Buy
128,351
+3,928
+3% +$143K 1.53% 30
2019
Q2
$5.11M Buy
124,423
+812
+0.7% +$32.2K 1.83% 21
2019
Q1
$4.98M Buy
123,611
+1,709
+1% +$68.4K 1.81% 24
2018
Q4
$5.05M Sell
121,902
-4,170
-3% -$173K 2.04% 20
2018
Q3
$5.27M Sell
126,072
-5,291
-4% -$204K 1.91% 23
2018
Q2
$4.52M Sell
131,363
-1,834
-1% -$62.7K 1.73% 24
2018
Q1
$4.49M Sell
133,197
-106
-0.1% -$3.64K 1.73% 25
2017
Q4
$4.58M Sell
133,303
-4,830
-3% -$165K 1.7% 25
2017
Q3
$4.68M Buy
138,133
+4,374
+3% +$141K 1.74% 25
2017
Q2
$4.26M Buy
133,759
+843
+0.6% +$26.6K 1.61% 27
2017
Q1
$4.31M Sell
132,916
-330
-0.2% -$10.4K 1.58% 28
2016
Q4
$4.11M Sell
133,246
-305
-0.2% -$9.31K 1.53% 28
2016
Q3
$4.29M Buy
133,551
+263
+0.2% +$8.79K 1.63% 26
2016
Q2
$4.45M Sell
133,288
-7,953
-6% -$254K 1.66% 26
2016
Q1
$3.97M Sell
141,241
-7,169
-5% -$205K 1.43% 31
2015
Q4
$4.54M Sell
148,410
-4,216
-3% -$133K 1.74% 25
2015
Q3
$4.55M Sell
152,626
-3,911
-2% -$125K 1.85% 23
2015
Q2
$4.98M Sell
156,537
-2,395
-2% -$78.1K 1.9% 19
2015
Q1
$5.25M Buy
158,932
+88
+0.1% +$2.8K 1.98% 18
2014
Q4
$4.69M Buy
158,844
+2,002
+1% +$57.4K 1.78% 23
2014
Q3
$4.4M Sell
156,842
-701
-0.4% -$19.7K 1.76% 22
2014
Q2
$4.44M Buy
157,543
+34
+0% +$969 1.71% 25
2014
Q1
$4.8M Sell
157,509
-1,792
-1% -$53.4K 1.9% 22
2013
Q4
$4.63M Sell
159,301
-5,164
-3% -$150K 1.82% 22
2013
Q3
$4.48M Sell
164,465
-774
-0.5% -$21.1K 1.88% 23
2013
Q2
$4.39M Buy
+165,239
New +$4.57M 1.89% 20

Other funds holding PFE

Monarch Capital Management's PFE Position: Q2 2026 in Review

Monarch Capital Management increased its Pfizer (PFE) stake by 2.2% in Q2 2026, buying an estimated $71.4K and bringing the position to 127,572 shares worth $3.07M. The position accounts for 0.7% of the portfolio, ranked #43.

Monarch Capital Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $6.84M in Q4 2021. 1,338 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Monarch Capital Management held 127,572 shares of Pfizer worth $3.07M as of Q2 2026.
  • Monarch Capital Management bought 2,730 Pfizer shares in Q2 2026, an estimated $71.4K.
  • Pfizer made up 0.7% of Monarch Capital Management's portfolio in Q2 2026, its #43 holding.
  • Monarch Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Monarch Capital Management's Pfizer position peaked at $6.84M in Q4 2021.
  • 1,338 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Monarch Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.